Experimental Pathology & Therapeutics Group
The group is dedicated to understanding cancer pathophysiological mechanisms and identifying biomarkers/molecular targets for precision oncology, by combining top-notch multi-omics, genetically engineered cancer cells, and animal models. It develops basic, translational, and clinical cancer research with the aim of improving cancer patient’s clinical management. The group closely collaborates with biopharmaceutical companies and has been actively committed to bringing improvements to health care through innovation, supporting clinical trials, new ventures and graduate training in oncology. It is also devoted to implementing oncology and cancer research units in Portuguese-speaking African countries.
COORDENADOR CIENTÍFICO
Lúcio Lara Santos, MD, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-0521-5655
Senior Surgeon
Associated Professor, Specialist in Oncology Surgery
Email: lucio.santos@ipoporto.min-saude.pt
TEAM
Senior Investigators
José Alexandre Ferreira, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-0097-6148/ 641C-9F20-41B1
Principal Investigator
Coordinator of the research line “Glycobiology of systems applied to cancer”; CEO of the start-up GlycoMatters Biotech (www.glycomatters.com)
Email: jose.a.ferreira@ipoporto.min-saude.pt
Carlos Alberto Palmeira de Sousa, PhD
ORCID ID/ CIÊNCIA ID: 0000-0002-4833-2202/ 781B-62F1-B0BA
Técnico Superior de Saúde do Laboratório de Imunologia
Senior Health Technician in the Immunology Laboratory
Coordinator of the research line “Cancer Immunology”; Assistant Professor in Immunology and Histopathology
Email: carlospalmeira@ipoporto.min-saude.pt
Luís Carlos Oliveira Lima, PhD
ORCID ID/ CIÊNCIA ID: 0000-0001-8152-9237/ 9F16-0E29-D9FC
Junior Researcher
Coordinator of the research line “Cancer Biomarker”
Email: luis.carlos.lima@ipoporto.min-saude.pt
Junior Researchers
Andreia Filipa Ferreira Peixoto, PhD
ORCID ID/ CIÊNCIA ID: 0000-0001-9514-0775/ 361D-5B5E-A5C1
Email: andreia.peixoto@ipoporto.min-saude.pt
Invited Researchers
Cristina Patrícia Mendes Santos, PhD
ORCID/ CIÊNCIA ID: 0000-0003-1437-9157/ D211-A545-54FC
Psycologist @ Associação Fraunhofer Research Portugal
Email: mendessantos.cristina@gmail.com
Elisabete Cristina Nunes Fernandes, PhD
ORCID/ CIÊNCIA ID: 0000-0002-9907-7432/ E31A-6197-4349
Science manager @UFP – University Fernando Pessoa
Email:
Maria do Céu dos Santos Silva Costa, PhD
ORCID/ CIÊNCIA ID: 000-0003-3766-2887/ 1915-FDC2-099B
Assistant Professor @ UFP – University Fernando Pessoa
Email: ccosta@ufp.edu.pt
Maria do Rosário Lima Viseu de Carvalho Pinto Leite, PhD
ORCID/ CIÊNCIA ID: 000-0003-4128-0494/ 5E1F-A422-C16D
Clinical Laboratory Geneticist @ CHTMAD
Email: mlleite@chtmad.min-saude.pt
Otília Pereira-Lopes, PhD
ORCID/ CIÊNCIA ID: 0000-0002-6199-4091/ 8C19-5295-FF32
Assistant Professor @ UFP – University Fernando Pessoa
Email: otilia@ufp.edu.pt
Pâmela Cristina Carvalho Borges, PhD
ORCID/ CIÊNCIA ID: 0000-0002-4491-9874/ F01A-BAE5-7AB6
Foreigner Researcher – Principal Investigator of Molecular Biology Lab @ Agostinho Neto University Hospital, Cape Verde
Email: palu15.18@gmail.com
Sofia do Rosário Alves Pereira, PhD
ORCID/ CIÊNCIA ID: 000-0002-3633-397x/ CF1A-9493-5C42
Assistant Professor @ UFP – University Fernando Pessoa
Email: sofia@ufp.edu.pt
PhD Students
Adriana Carneiro, MSc
ORCID/ CIÊNCIA ID: 0000-0003-1905-6250/ 481E-1A5C-FD18
INL Braga & CI-POP
Email: adriana.carneiro@ipoporto.min-saude.pt
Ana Carolina Fernandes Vieira de Castro, MSc
ORCID/ CIÊNCIA ID: 0000-0001-8156-4470/ BE18-11D8-B606
CI-IPOP
Email: ana.castro@ipoporto.min-saude.pt
Andreia Rafaela Linhares Miranda, MSc
ORCID/ CIÊNCIA ID: 0000-0002-5441-4888/ 1718-50AE-1648
CI-IPOP
Email: i37220@ipoporto.min-saude.pt
Catarina Alexandra da Rocha Rodrigues, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1305-8055/ 321E-40C9-FC31/ 321E-40C9-FC31
CI-IPO & i3S
Email: catarina.rodrigues@ipoporto.min-saude.pt
Catarina Alves Pinto, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1465-7666/ 2F1F-8115-52CE
CI-IPOP & ICBAS & University of Tokyo
Email: up201402615@edu.icbas.up.pt
Clara Alice Gentil Daher Mota, MSc
ORCID/ CIÊNCIA ID: 0000-0002-2938-1623/ 1611-4013-2CBB
FADEUP &CI-IPOP
Email: clara.mota@ipoporto.min-saude.pt
Cristiana Milhazes Gaiteiro, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5438-1679/ 6717-DB97-FF86
CI-IPOP
Email: i12812@ipoporto.min-saude.pt
Daniel Mateus Gonçalves, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5388-870/ 9D14-B66F-A1CF
Instituto Superior Técnico & CI-IPOP
Email: dmateusgoncalves@tecnico.ulisboa.pt
Daniela Rocha Santos, MSc
ORCID/ CIÊNCIA ID: 0000-0003-1081-5142/ 4617-DBEA-8AE6
CI-IPOP
Email: daniela.r.santos@ipoporto.min-saude.pt
Dylan Gomes Ferreira, MSc
ORCID/ CIÊNCIA ID: 0000-0001-9224-0121/ AA12-CF31-3A82
CI-IPOP & CIMA Institute
Email: i38795@ipoporto.min-saude.pt
Eliana Janine de Paiva Soares, MSc
ORCID/ CIÊNCIA ID: 0000-0002-1586-7120/ 9A1D-8326-6C19
CI-IPOP& UA
Email: eliana.paiva.soares@ipoporto.min-saude.pt
João Miguel Monteiro Antunes, MSc
ORCID/ CIÊNCIA ID: 0000-0002-9904-5115/ E110-6373-AB6D
FADEUP & CI-IPOP
Email: joao.monteiro.antunes@ipoporto.min-saude.pt
Mafalda Barbosa Pedrosa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-3222-731X/ CC1F-AF12-787C
FADEUP & CI-IPO & UA
Email: i37305@ipoporto.min-saude.pt
Maria de Fátima Sousa e Santos, MSc
ORCID/ CIÊNCIA ID: 0000-0003-3796-2054/ CB1E-EE01-ED1C
CI-IPOP
Email: maria.fatima.santos@ipoporto.min-saude.pt
Mariana Pinto de Sousa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5232-2384/ 151A-5FC2-8034
CI-IPOP
Email: mariana.p.sousa@ipoporto.min-saude.pt
Marta Filipa Relvas dos Santos, MSc
ORCID/ CIÊNCIA ID:: 0000-0001-5764-5414/ EE19-E89D-2D92
CI-IPOP & FCUP
Email: marta.relvas.santos@ipoporto.min-saude.pt
Michelle Shereen Alves Castanheira, MSc
ORCID/ CIÊNCIA ID:: 0009-0005-7368-687X /4311-D422-CF14
GRAQ- REQUIMTE & CI-IPOP
Email: michelle_castanheira@hotmail.com
Nuno Henrique Oliveira Jorge, MSc
ORCID/ CIÊNCIA ID: 0000-0003-5531-0557/ D716-29E8-991
FADEUP &CI-IPOP
Email: nuno.jorge@ipoporto.min-saude.pt
Patrícia Pinto de Pinho, MSc
CIÊNCIA ID:: D21B-B93A-6001
CITAB & CI-IPOP
Email: patriciapintopinho@hotmail.com
Pedro Miguel dos Reis Cruz, MD, MSc
ORCID/ CIÊNCIA ID: 0000-0001-8813-0632/ 0610-621F-B88A
CI-IPOP
Email: pedro.reis.cruz@ipoporto.min-saude.pt
Rui Filipe Neves Freitas, MSc
ORCID/ CIÊNCIA ID: 0000-0003-0723-8719/ 2B13-9E7D-E20B
CI-IPOP & I3s
Email: rui.freitas@ipoporto.min-saude.pt
Samuel da Silva Barbosa, MSc
ORCID/ CIÊNCIA ID: 0000-0001-5364-7340/ 0713-CF7A-0417
FADEUP & CI-IPOP
Email: i37306@ipoporto.min-saude.pt
Sofia Ribeiro Cotton, MSc
ORCID/ CIÊNCIA ID: 0000-0002-8112-5619/ 081F-D38F-8B7A
CI-IPOP & I3s
Email: sofia.ribeiro.cotton@ipoporto.min.saude.pt
Research Assistants
Beatriz Marinho Santos, MSc
ORCID/ CIÊNCIA ID: 0009-0004-2783-4950/ 071C-C3F1-1D95
Email: beatriz.santos@ipoporto.min-saude.pt
Beatriz da Silva Matos, MSc
ORCID/ CIÊNCIA ID: 0000-0002-9333-5525/ 8E17-4276-A691
Email: beatriz.matos@ipoporto.min-saude.pt
Eduardo da Silva Ferreira, MSc
ORCID/ CIÊNCIA ID: 0009-0003-3258-8451/ E61B-3A6A-E8AE
Email: i37310@ipoporto.min-saude.pt
Mariana Gonçalves Eiras, MSc
ORCID/ CIÊNCIA ID: 0009-0006-7483-4771/ F310-BAED-C2E9
Email: mariana.eiras@ipoporto.min-saude.pt
Martina Dourado Gonçalves, MSc
ORCID/ CIÊNCIA ID: 0009-0004-6311-3990/ C410-3A72-CC85
Email: martina.goncalves@ipoporto.min-saude.pt
MSc Students
Camila Adriana Gonçalves Lourenço
CIÊNCIA ID: 391C-D972-B9EA
Email: camila.lourenco@ipoporto.min-saude.pt
Débora Filipa Pinto
CIÊNCIA ID: 2619-D353-8599
Email: debora.pinto@ipoporto.min.saude.pt
Other collaborators
Dora Maria Barrocas Bernardo, MSc, Oncology pharmacist
ORCID/ CIÊNCIA ID: 0000-0002-9755-4362/ 5B17-1115-3B7A
Luís Pedro Fernandes Afonso, MSc, Pathologist
ORCID/ CIÊNCIA ID: 0000-0002-6354-7332/ FA1F-3698-B309
Mariana Macedo Alves Peyroteo Gomes, MD, MSc, Surgeon
ORCID/ CIÊNCIA ID: 0000-0002-0941-2533
Pedro Carvalho Martins, MD, MSc, Surgeon
ORCID/ CIÊNCIA ID: 0000-0002-1828-078X
Aims
Foreseeing precise clinical interventions, the group has four teams:
The Infection in Cancer and Clinical Translation team aims to study the carcinogenesis caused by infectious agents foreseeing clinical intervention. It also focuses on defining personalized risk mitigation programs (e.g. perioperative care).
The systems cancer glycobiology team dedicates to understanding cancer glycosylation by integrating multi-omics approaches and identifying cancer specific signatures for patient stratification and targeted interventions.
The cancer immunology team focuses on mechanisms of immunotherapy resistance and pre-clinical assessment of combination therapies in cellular and animal models.
The cancer biomarkers team studies circulating cancer cells and non-invasive biomarkers envisaging precision oncology.
PROJECTS WITH EXTERNAL FUNDING
RESOLVE: Rational Design of Multivalent Glycocode-Inspired Nanovaccines for Gastric Cancer Immunotherapy
Funded by FCT
Ref: DOI: 10.54499/PTDC/MED-OUT/2512/2021
Period: 01/01/2022 – 31/12/2024
Budget: 128 305.00€
PI: José Alexandre Ferreira
RESOLVE aims at a comprehensive interrogation of the gastric cancer glycoproteome for unique molecular signatures to improve patient stratification. It also plans to translate clinically relevant signatures into innovative cancer glycovaccines exploiting proprietary cutting-edge glycoengineered nanovehicles. These new generation of glycosylated vaccine vehicles can specifically deliver immunogenic cargos to antigen presenting cells, unleashing otherwise compromised immune responses against cancer cells. The objective is to setup the pre-clinical basis for an innovative immunotherapy for cancer.
Publications
Peixoto A, Miranda A, Santos LL, Ferreira JA. A roadmap for translational cancer glycoimmunology at single cell resolution. J Exp Clin Cancer Res. 2022 41(1):143. doi: 10.1186/s13046-022-02335-z.
REVERENT: Pre-clinical Validation of a Glycocode-inspired Vaccine for Bladder Cancer Immunotherapy
Funded by FCT
Ref: 2022.03621.PTDC
Period:01/03/2023 – 31/08/2024
Budget: 49 507.07€
PI: Andreia Peixoto Co-PI: José Alexandre Ferreira
The project aims to validate a glycovaccine for bladder cancer in a pre-clinical context, using relevant animal tumor models, with the translational intent for clinical studies.
Phosphoproteomics of hypoxic and glucose deprived bladder cancer cells: the missing link towards systems oncology
Funded by European Proteomics Infrastructure Consortium
Ref: EPIC-XS-0000341
Period:01/06/2021 – 31/05/2023
PI: José Alexandre Ferreira in collaboration with Heck’s Lab at Utrecht University
Hypoxia resulting from ineffective vascularization due to uncontrolled cell growth is a relevant microenvironmental feature of more aggressive tumours, driving main cancer hallmarks. This event is accompanied by nutrient shortage, however the molecular and functional adaptations experienced by cancer cells under both oxygen and nutrient depletion remains poorly understood. Multi-omics systems biology approaches, with emphasis on phosphoproteomics and glycoproteomics, are being used to comprehensively characterize hypoxic microenvironments envisaging precision interventions.
Publications
Peixoto A, Freitas R, Ferreira D, Relvas-Santos M, Paulo P, Cardoso C, Soares J, Gaiteiro C, Palmeira C, Teixeira F, Ferreira R, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation. bioRvx 2021 doi: https://doi.org/10.1101/2021.02.14.431133
IPOScore: Predicting the risk of complications of surgical treatment and define prognosis of cancer patients through clinical and biopathological data integration
Funded by FCT
Ref: DSAIPA/DS/0042/2018
Period:01/01/2019 – 31/07/2022
Budget: 31 163.00€
PI: Andreia Peixoto Co-PI: José Alexandre Ferreira
This project intends to apply an innovative approach based on data-driven modeling that integrates clinical, biopathological and physiological data of patients with cancer to predict the risk of (post-)operative complications. The expected outcome is the creation of an user-friendly online platform, which includes a database to store/manage the data collected in a structured format, computational approaches and prediction models to calculate a specific risk index score for the Portuguese population. The platform will provide an added-value to surgeons in oncological hospitals as an intelligent clinical decision support system.
Publications
Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA. Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm. 2019 570:118646. doi: 10.1016/j.ijpharm.2019.118646.
Fernandes A, Rodrigues J, Lages P, Lança S, Mendes P, Antunes L, Santos CS, Castro C, Costa RS, Lopes CS, da Costa PM, Santos LL. Root causes and outcomes of postoperative pulmonary complications after abdominal surgery: a retrospective observational cohort study. Patient Saf Surg. 2019 13:40. doi: 10.1186/s13037-019-0221-5.
Fernandes E, Sores J, Cotton S, Peixoto A, Ferreira D, Freitas R, Reis CA, Santos LL, Ferreira JA. Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics. 2020 10(11):4903-4928. doi: 10.7150/thno.42480.
Fernandes A, Rodrigues J, Antunes L, Lages P, Santos CS, Moreira-Gonçalves D, Costa RS, Sousa JA, Dinis-Ribeiro M, Santos LL. Development of a preoperative risk score on admission in surgical intermediate care unit in gastrointestinal cancer surgery. Perioper Med (Lond). 2020 9:23. doi: 10.1186/s13741-020-00151-7.
Sousa Menezes A, Fernandes A, Rocha Rodrigues J, Salomé C, Machado F, Antunes L, Castro Silva J, Monteiro E, Lara Santos L. Optimizing classical risk scores to predict complications in head and neck surgery: a new approach. Eur Arch Otorhinolaryngol. 2021 278(1):191-202. doi: 10.1007/s00405-020-06133-1.
PROTECT: Prehabilitation to enhance cancer treatment in patients with adenocarcinoma of the gastroesophageal junction and the stomach
Funded by FCT
Ref: PTDC/SAU-DES/7945/2020
Period: 01/01/2021 – 31/12/2023
Budget: 135 695.00€
PI: Lúcio Lara Santos
The PROTECT project envisions the multimodal prehabilitation of proximal gastric and gastroesophageal junction cancer patients to minimize the burden without compromising the safety and efficacy of anti-cancer treatment.
DCMatters: Combination of Dendritic Cell Vaccine with Immune Checkpoint Inhibitors as First-Line Therapy in Patients
Funded byFEDER
Ref: NORTE-01-0247-FEDER-047212
Budget: 822 007.92€
PI: Lúcio Lara Santos
The DCMatters project aims to develop and manufacture a new generation of dendritic cell (DC) vaccines with greater capacity to induce an anti-tumour response, by optimizing the manufacturing method using chemoinformatic tools and validating it in vitro and in vivo.
Laserthermia: Synergistic antitumor effect of combined laser thermotherapy and immunomodulators in malignant melanoma
Funded by Clinical Laserthermia Systems AB
Ref: PI 130-CI-IPOP-125-2019
Budget: 79 347.64€
PI: Carlos Alberto Palmeira de Sousa Co-PI: Lúcio Lara Santos
The Laserthermia project aims to evaluate the synergistic antitumor effect of laser-based thermotherapy and clinically implemented immunomodulators in poorly immunogenic B16F10 melanoma mouse models.
PROJECTS WITH INTERNAL FUNDING
OptimizingLiverMet: Immunological and circulating tumour cells evaluation in colorectal cancer liver metastasis
REF.: PI 77-CI-IPOP-47-2016
Budget: 47 172.39€
PI: Lúcio Lara Santos Co-PI: Luís Lima
Colorectal cancer is common in Portugal, often leading to liver metastases. Hepatic resection is a primary treatment, with recent advances in systemic therapies improving prognosis. However, challenges like liver recurrences and adverse events persist. Immunotherapy, especially with checkpoint inhibitors like Pembrolizumab, has shown promise for cancers with high mutational loads. Our study aims to analyze immune markers in primary tumors and liver metastases, and assess circulating tumor cells in blood, to optimize treatment strategies for colorectal cancer patients with liver metastases.
GlycoBodies: Development of monoclonal antibodies for chemoresistant bladder cancer based on glycobiomarkers
Funded by IPO Research Center
Ref: CI-IPOP-58-2015
Budget: 223 950.99€
Period:01/01/2015 – 31/12/2024
PI: José Alexandre Ferreira Co-PI: Lúcio Lara Santos
The project devotes to a comprehensive characterization of the bladder cancer glycome and glycoproteome across the multiple pathological manifestations of the disease, with emphasis on tumours not responding to chemotherapy. The overall aim is to identify cancer specific signatures and develop theranostic antibodies for aggressive cells precise targeting.
Publications
Azevedo R, Soares J, Gaiteiro C, Peixoto A, Lima L, Ferreira D, Relvas-Santos M, Fernandes E, Tavares A, Cotton S, Daniel-da-Silva AL, Santos LL, Vitorino R, Amado F, Ferreira JA. Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer. Talanta. 2018 184:347-355. doi: 10.1016/j.talanta.2018.03.028.
Azevedo R, Soares J, Peixoto A, Cotton S, Lima L, Santos LL, Ferreira JA. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018 36(5):221-236. doi: 10.1016/j.urolonc.2018.02.004.
Peixoto A, Relvas-Santos M, Azevedo R, Santos LL, Ferreira JA. Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks. Front Oncol. 2019 9:380. doi: 10.3389/fonc.2019.00380.
Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, Martins G, Barros A, Santos LL, Sarmento B, Ferreira JA. Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential. Int J Pharm. 2019 570:118646. doi: 10.1016/j.ijpharm.2019.118646.
Fernandes E, Sores J, Cotton S, Peixoto A, Ferreira D, Freitas R, Reis CA, Santos LL, Ferreira JA. Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics. 2020 10(11):4903-4928. doi: 10.7150/thno.42480.
Fernandes E, Freitas R, Ferreira D, Soares J, Azevedo R, Gaiteiro C, Peixoto A, Oliveira S, Cotton S, Relvas-Santos M, Afonso LP, Palmeira C, Oliveira MJ, Ferreira R, Silva AMN, Lara Santos L, Ferreira JA. Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells. Cancers (Basel). 2020 12(4):861. doi: 10.3390/cancers12040861.
Ferreira JA, Relvas-Santos M, Peixoto A, M N Silva A, Lara Santos L. Glycoproteogenomics: Setting the Course for Next-generation Cancer Neoantigen Discovery for Cancer Vaccines. Genomics Proteomics Bioinformatics. 2021 19(1):25-43. doi: 10.1016/j.gpb.2021.03.005.
Peixoto A, Ferreira D, Azevedo R, Freitas R, Fernandes E, Relvas-Santos M, Gaiteiro C, Soares J, Cotton S, Teixeira B, Paulo P, Lima L, Palmeira C, Martins G, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. J Exp Clin Cancer Res. 2021 40(1):191. doi: 10.1186/s13046-021-01988-6.
Cotton S, Ferreira D, Soares J, Peixoto A, Relvas-Santos M, Azevedo R, Piairo P, Diéguez L, Palmeira C, Lima L, Silva AMN, Lara Santos L, Ferreira JA. Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness. Int J Mol Sci. 2021 22(4):1664. doi: 10.3390/ijms22041664.
Freitas R, Relvas-Santos M, Azevedo R, Soares J, Fernandes E, Teixeira B, Santos LL, Silva AMN, Ferreira JA. Single-pot enzymatic synthesis of cancer-associated MUC16 O-glycopeptide libraries and multivalent protein glycoconjugates: a step towards cancer glycovaccines. New Journal of Chemistry 45 2021, 9197-9211, doi:10.1039/d0nj06021f.
Peixoto A, Cotton S, Santos LL, Ferreira JA. The Tumour Microenvironment and Circulating Tumour Cells: A Partnership Driving Metastasis and Glycan-Based Opportunities for Cancer Control. Adv Exp Med Biol. 2021 1329:1-33. doi: 10.1007/978-3-030-73119-9_1.
Peixoto A, Freitas R, Ferreira D, Relvas-Santos M, Paulo P, Cardoso C, Soares J, Gaiteiro C, Palmeira C, Teixeira F, Ferreira R, Oliveira MJ, Silva AMN, Santos LL, Ferreira JA. Metabolomics, Transcriptomics and Functional Glycomics Reveals Bladder Cancer Cells Plasticity and Enhanced Aggressiveness Facing Hypoxia and Glucose Deprivation. bioRvx 2021 doi: https://doi.org/10.1101/2021.02.14.431133.
Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, Brandão A, Fernandes E, Azevedo R, Palmeira C, Freitas R, Miranda A, Osório H, Prieto J, Lima L, Silva AMN, Santos LL, Ferreira JA. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022 12(7):3150-3177. doi: 10.7150/thno.67409.
Peixoto A, Miranda A, Santos LL, Ferreira JA. A roadmap for translational cancer glycoimmunology at single cell resolution. J Exp Clin Cancer Res. 2022 41(1):143. doi: 10.1186/s13046-022-02335-z.
Selected publications (up to five)
Freitas R, Ferreira E, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Santos B, Gonçalves M, Quintas S, Peixoto A, Palmeira C, Silva AMN, Santos LL, Oliveira MJ, Sarmento B, Ferreira JA. Targeted and Self-Adjuvated Nanoglycovaccine Candidate for Cancer Immunotherapy. ACS Nano 2024 18(14):10088-10103. doi: 10.1021/acsnano.3c12487; PMID: 38535625
Freitas R, Miranda A, Ferreira D, Relvas-Santos M, Castro F, Ferreira E, Gaiteiro C, Soares J, Cotton S, Gonçalves M, Eiras M, Santos B, Palmeira C, Correia MP, Oliveira MJ, Sarmento B, Peixoto A, Santos LL, Silva AMN, Ferreira JA. A multivalent CD44 glycoconjugate vaccine candidate for cancer immunotherapy. J Control Release 2024 367:540-556. doi: 10.1016/j.jconrel.2024.01.065; PMID: 38301927
Carneiro A, Piairo P, Matos B, Santos DAR, Palmeira C, Santos LL, Lima L, Diéguez L. Minimizing false positives for CTC identification. Anal Chim Acta. 2024 1288:342165. doi: 10.1016/j.aca.2023.342165; PMID: 38220297
Santos DAR, Gaiteiro C, Santos M, Santos L, Dinis-Ribeiro M, Lima L. MicroRNA Biomarkers as Promising Tools for Early Colorectal Cancer Screening-A Comprehensive Review. Int J Mol Sci. 2023 24(13):11023. doi: 10.3390/ijms241311023. PMID: 37446201;
Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P, Brandão A, Fernandes E, Azevedo R, Palmeira C, Freitas R, Miranda A, Osório H, Prieto J, Lima L, Silva AMN, Santos LL, Ferreira JA. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics 2022 12:3150. doi: 10.7150/thno.67409; PMID: 35547758
NATIONAL COLLABORATIONS
André Silva – Faculty of Sciences of University of Porto
Bruno Neves – University of Aveiro
Celso Reis; Cristina Xavier; Fátima Gartner; Isabel Castro; João Vinagre; Luísa Pereira; Maria Helena Vasconcelos; Maria José Oliveira; Paula Soares; Raquel Almeida; Sérgia Velho; Nuno Mendes – i3S-Instituto de Investigação e Inovação em Saúde da Universidade do Porto
Daniel Moreira Gonçalves – Faculty of Desport of University of Porto
Francisco Amado, Rita Ferreira, Rui Vitorino – Chemistry Department, University of Aveiro
Lorena Dieguez – International Iberian Nanotechnology Laboratory (INL)
Lucília Saraiva – School of Medicine and Biomedical Sciences of University of Porto
Marlene Santos – The School of Health of Polytechnic Institute of Porto
Miguel Oliveira – University of Minho – 3B’s; Braga
Paula Oliveira – University of Trás-os-Montes and Alto Douro
Paula Videira, Angelina Palma, Rafael Costa – NOVA School of Science and Technology, NOVA University Lisbon
Rui Henriques – IST Técnico-University of Lisbon
INTERNATIONAL COLLABORATIONS
André Carvalho – International Agency for Research on Cancer/ World Health Organization; France
Bruno Vedrine – Oncocellex at BUSI Incubateur d’Entreprises Auvergne; France
Carla Carrilho – Facuty of Medicine of University Eduardo Mondlane; Mozambique
Fernando Miguel – Angolan Institute for Cancer Control – IACC, Angola
Giovanni De Manzoni – University of Verona; Italy
Hervé Luche – French Institute of Health and Medical Research | Inserm, France
Isabel M. dos Santos Silva – London School of Hygiene & Tropical Medicine; United Kingdom
Jesus Prieto, Juan José Lasarte – Center for Applied Medical Research (CIMA) of the University of Navarre; Spain
João Curado – Flomics; Spain
Laura Bermejo – Ramón y Cajal Institute for Health Research (IRYCIS); Spain
Luke Cossins – Universal Biosensors (UBI); Australia
Noel Miranda – Leiden University Medical Center (LUMC); Netherlands
Rita Azevedo – Institut Pasteur; France
Rogier Louwen – CCassured; Netherlands
Yvette van kooyk – Amsterdam UMC, Vrije Universiteit Amsterdam; Netherlands